$PATH

Ramani Hitesh sold $831K of PATH

Ramani Hitesh (Chief Accounting Officer) sold 50,000 shares of UiPath, Inc. (PATH) at an average of $16.62 ($16.50–$16.75, $0.83M total) across 2 trades over 2026-08-13 to 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ramani Hitesh
Published Aug 14, 2026, 8:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:49 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PATH
Neutral
high confidence
Mentioned
$PATH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PATHNeutralLow
01

Why it matters

The only new information is the disclosed sale size, timing, and price range, plus confirmation that it was executed under a pre-arranged 10b5-1 plan. No operational or financial guidance changes are included.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make this more of a sentiment datapoint than a catalyst.

03

What to watch

The filing does not indicate whether additional sales occurred outside the disclosed window, nor does it provide context on total planned sales or remaining tranche size.

Relevance 4/10Novelty 5/10Timing: Filed on 2026-08-14 after two sales on 2026-08-13 and 2026-08-14.

Background

The article is a SEC Form 4 insider transaction disclosure for UiPath, Inc. (PATH) by Chief Accounting Officer Ramani Hitesh.

Company-level read

Ticker impact

$PATHNeutralHigh confidence
Context

UiPath Form 4 shows CFO Ramani Hitesh sold 50,000 shares in open-market trades at about $16.50 to $16.75 (10b5-1).

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment rather than a durable repricing.

Evidence & confidence

The filing is a routine Form 4 open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying guidance, operational change, or regulatory/legal event disclosed.

Market effects

Minimal. Insider selling under 10b5-1 in a single software name does not materially change sector fundamentals.

Minimal.

Minimal.

Counterpoint

Because the trades are under a 10b5-1 plan, the sale may reflect scheduled liquidity rather than bearish expectations, so any negative read-through may be overstated.

Key entities

  • UiPath, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Ramani Hitesh

    Chief Accounting Officer who sold shares via open-market trades under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PLTRHighAI 9/10

Palantir Rockets 16% After Q2 Blowout; C3.ai, UiPath Sit Out the Rally

Palantir Technologies reported Q2 2026 revenue of $1.94B, up 92.8% YoY, beating $1.81B consensus, and raised FY2026 revenue guidance to about $8.15B. U.S. commercial total contract value reached a record $2.1B. Shares rose about 16% to $145.50 after Deutsche Bank upgraded to Buy with a $200 target; C3.ai and UiPath did not rally.

$PLTRMed

JFrog, Zscaler, Palo Alto Networks, Shopify, and UiPath Shares Are Soaring, What You Need To Know

In Tuesday premarket trading, Palantir’s (PLTR) reported Q2 results and raised full-year revenue outlook drove a broad rally in enterprise software and cybersecurity peers. The article cites Palantir’s 26% jump and links the move to lower Treasury yields after geopolitical de-escalation. It also lists gains for JFrog (FROG), Zscaler (ZS), Palo Alto Networks (PANW), Shopify (SHOP), and UiPath (PATH).

$PATHMed

UiPath (NYSE:PATH) Shares Fall as Q2 Outlook Indicates Reduced ARR Growth

NEW YORK, July 30, 2026, 2:01 p.m. EDT — Shares of UiPath NYSE:PATH declined after the company forecasted slower additions to annualized recurring revenue for the second quarter. The stock dropped 3.3% to $12.18 in early U.S. trading. Initial estimates indicate Q2 guidance suggests net new ARR between $28 million and $33 million. Initial estimate: market value, adjusted for cash, is approximately 2.8 times the projected revenue for fiscal 2027. UiPath shares declined even as U.S.

$PATHMed

PATH Stock Slips As UBS Trims Price Target

UiPath (PATH) shares were up about 7.3% on AI automation optimism, but UBS cut its price target to $12 from $13 while keeping a Neutral rating. Street consensus remains Hold with a mean target near $13.47 versus a price around $10.81. The article also cites UiPath’s annual revenue of about $1.61B and recent quarterly net income of about $22.5M.

$PATHMed

UiPath shares rebound as Wall Street warms to its AI-agent pivot

UiPath shares rebounded about 15% over five days after the company reported its first-quarter GAAP operating profit of $28m and GAAP profit for the first time in a first quarter, following a loss a year earlier. Revenue rose 17% to $418m; annual recurring revenue reached $1.9bn (+12%). UiPath is pivoting to AI agents, including its WorkFusion acquisition.

$PATHMedAI 9/10

Stock Market Today, June 1: Stock Market Today, June 1: UiPath Rises After Strong Q1 Results and Raised Outlook

UiPath (NYSE:PATH) rose 11.77% to close at $13.10 after reporting fiscal Q1 2027 results and raising guidance, according to the company. The report cited 17% year-over-year revenue growth to $418 million, annual recurring revenue of $1.901 billion (+12%), and positive GAAP operating income of $28 million. Trading volume was 65.5 million shares.